Skip to content

Randomized Trial of Web-Delivered Acceptance Therapy for Smoking Cessation (WebQuit)

Randomized Trial of Web-Delivered Acceptance Therapy for Smoking Cessation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01812278
Enrollment
2637
Registered
2013-03-18
Start date
2014-03-24
Completion date
2019-12-31
Last updated
2020-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Smoking

Brief summary

The goal of this study is to determine whether the ACT website provides higher quit rates than a current standard smoking cessation website.

Interventions

BEHAVIORALACT
BEHAVIORALCBT

Sponsors

Kaiser Permanente
CollaboratorOTHER
National Cancer Institute (NCI)
CollaboratorNIH
National Institutes of Health (NIH)
CollaboratorNIH
Fred Hutchinson Cancer Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
Yes

Inclusion criteria

* age 18 or older * smokes at least five cigarettes daily for at least past 12 months * wants to quit in next 30 days * willing to be randomly assigned to either group * resides in US * has at least weekly access to a high speed Internet connection and email * willing and able to read in English * not participating in other smoking cessation interventions (including our other intervention studies * has never used the Smokefree.gov website * willing to complete all three follow-up surveys * provide email, phone, and mailing address * provide contact information for two collaterals (e.g., relatives). * does not have family, friends, or other household members participating

Exclusion criteria

* The

Design outcomes

Primary

MeasureTime frameDescription
30-day point prevalence abstinence12 month post randomizationNo smoking in the past 30 days, as reported 12 month post treatment.

Secondary

MeasureTime frameDescription
7-day, 24-hour, and 30-day point prevalence quit rates3 months, 6 months, and 12 months post treatment12 months: 24-hour and 7-day point prevalence quit rates. 3 and 6 months: 24-hour, 7-day, and 30-day point prevalence quit rates. Across 3, 6, and 12 month timepoints, the repeated 30-day point prevalence abstinence.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026